This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Firms Expecting Clinical Trial Results

Company: BioMarin Pharmaceuticals (BMRN - Get Report)

Drug/indication: Peg-Pal for phenylketonuria (PKU)

Estimated timing: Third quarter

Recent stock performance: At $19, the stock is flat for the year, off its recent high of $25 reached in May.

Peg-Pal is a follow-on therapy for PKU that is being developed as a treatment for patients who do not respond to Biomarin's currently marketed PKU drug Kuvan. This phase II study treats 35 patients with PKU for 16 weeks.

4 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
ARIA $9.12 -0.33%
BMRN $116.09 0.15%
AZN $68.53 0.96%
CORT $5.88 -1.80%
CYCC $0.89 0.00%

Markets

DOW 18,078.37 +54.31 0.30%
S&P 500 2,114.91 +6.62 0.31%
NASDAQ 5,021.9030 +16.5120 0.33%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs